🇺🇸 FDA
Pipeline program

Lutrate Depot Trimestral 22,5 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 150 mg film-coated tablets, Femara 2.5 mg Tablets, Arimidex® 1 mg film-coated tablets, Zoladex 10,8 mg implantat, Aromasil 25 mg comprimidos recubiertos, Verzenios 100 mg film-coated tablets, Zoladex 3,6 mg implantat, Kisqali 200 mg film-coated tablets, Lutrate Depot Mensual 3,75 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 50 mg film-coated tablets

GEICAM/2023-09

Approved small_molecule active

Quick answer

Lutrate Depot Trimestral 22,5 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 150 mg film-coated tablets, Femara 2.5 mg Tablets, Arimidex® 1 mg film-coated tablets, Zoladex 10,8 mg implantat, Aromasil 25 mg comprimidos recubiertos, Verzenios 100 mg film-coated tablets, Zoladex 3,6 mg implantat, Kisqali 200 mg film-coated tablets, Lutrate Depot Mensual 3,75 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 50 mg film-coated tablets for Early Breast Cancer is a Approved program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Early Breast Cancer
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials